Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Drugs Today (Barc)
; 49(7): 447-56, 2013 07.
Article
de En
| MEDLINE
| ID: mdl-23914353
ABSTRACT
Omacetaxine mepesuccinate is a protein synthesis inhibitor that causes apoptosis of chronic myeloid leukemia cells without binding to the BCR-ABL tyrosine kinase that is implicated in the pathogenesis of this disease. It has been approved for the treatment of chronic myeloid leukemia in patients with resistance to two or more tyrosine kinase inhibitors and is emerging as an important agent in countering the highly resistant T315I mutation. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of omacetaxine mepesuccinate in the current milieu of tyrosine kinase inhibitor-dominant therapy of chronic myeloid leukemia.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Leucémie myéloïde chronique BCR-ABL positive
/
Harringtonines
Limites:
Humans
Langue:
En
Journal:
Drugs Today (Barc)
Sujet du journal:
MEDICINA OCUPACIONAL
/
SAUDE AMBIENTAL
Année:
2013
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique